pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Riabni
drug · antibody
save

rituximab biosimilar

pre_registrationupdated 6mo ago
by Dr. Reddy's Laboratories Ltd🔗 ChEMBL
community read0 votes

Antibody drug with a maximum clinical stage of Approval (across all indications), with 10 approved and 114 investigational indications.

indications

indications
DLBCLRheumatoid Arthritis

targets

B-lymphocyte antigen CD20

all catalysts(0)

nothing on the calendar yet

Trials studying rituximab biosimilar

  • phase3A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)recruitingn=1,046
  • phase3A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)recruitingn=960
  • phase2A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)recruitingn=594
  • phase3A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)active not recruitingn=300
  • phase2A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphomarecruitingn=97
  • phase2A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)active not recruitingn=60
  • phase3Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphomacompletedn=317

News(8)

  • Could we see 10 Chinese Big Pharmas within a decade? Some CEOs think so
    For executives at many of the Chinese drug developers who spoke to Fierce, the real prize is a seat at the Big Pharma table. In recent years, this objective has moved from a vague aspiration to a c…
    fiercebiotech · 10d ago
  • Celltrion picks up another Kaigene autoimmune antibody for up to $580.5M
    Celltrion has licensed a preclinical antibody targeting autoimmune conditions from Maryland-based biotech Kaigene in a deal worth up to $580.5 million, marking another step in the South Korean drug…
    fiercebiotech · 26d ago
  • Epkinly data only one of Genmab's make-or-break readouts ahead of steep sales erosion
    Bracing for patent losses on its cornerstone product Darzalex, Genmab has bet its future on three cancer programs that will deliver pivotal readouts in quick succession.
    biospace · 28d ago
  • ‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the future
    When recombinant DNA pioneer Herbert Boyer, Ph.D., first got a call from venture capitalist Robert Swanson about starting a company, the savvy scientist wasn’t sure a meeting would be worth his time.
    fiercebiotech · 1mo ago
  • China’s Henlius carves out $440M T-cell engager deal with Amberstone
    Fosun Pharma subsidiary Henlius Biotech has signed a $440 million biobucks deal with California-based Amberstone Biosciences to work on T-cell engagers.
    fiercebiotech · 1mo ago
  • Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug
    Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs.
    biopharma_dive · 1mo ago
  • Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program
    The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Brukinsa data.
    biopharma_dive · 4mo ago
  • A Spanish biotech banks $87M to make differentiated ADCs
    Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced forms of breast and colorectal cancers.
    biopharma_dive · 5mo ago
brand
Riabni
trade names
Blitzima, Mabthera, Mabthera rituxan, Ritemvia, Rituxan, Rituximab component of rituxan hycela
generic
rituximab-arrx
MOA
B-lymphocyte antigen CD20 binding agent
indication
Unspecified Cancer
phase
pre_registration
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?